The Federal Government has granted N24 billion in tax waivers to local drug manufacturers to stimulate the domestic production of medicines, medical equipment, and other essential healthcare products.
Muhammad Pate, the Coordinating Minister of Health and Social Welfare, confirmed the incentives are being implemented to strengthen Nigeria’s healthcare supply chain and reduce the country’s heavy reliance on imported pharmaceuticals. The move is designed to provide much-needed financial relief to domestic manufacturers facing high operational costs.
According to the minister, these tax waivers to boost local production were introduced under a presidential executive order signed in 2024. The order specifically targets the manufacturing sector to ensure that critical healthcare commodities are produced within the country.
Strengthening the domestic healthcare supply chain
For years, the Nigerian pharmaceutical sector has grappled with significant challenges, including the high cost of importing Active Pharmaceutical Ingredients (APIs), foreign exchange volatility, and inadequate infrastructure. These factors have often resulted in the high cost of drugs for the average Nigerian and frequent shortages of essential medicines.
By providing these tax reliefs, the government aims to lower the cost of production for local companies. This, in turn, is expected to make essential medicines more affordable for patients and reduce the national expenditure on pharmaceutical imports. The scope of the incentives extends beyond basic drugs to include the manufacturing of medical devices and other critical healthcare technology.
Industry experts suggest that the N24 billion relief could serve as a catalyst for much-needed capital investment in local factories. Increased production capacity would not only improve health security but also create employment opportunities within the manufacturing sector.
The implementation of the 2024 executive order marks a shift in the government’s approach to healthcare, moving from mere regulation to active economic support for local producers. However, the success of this initiative will depend on the consistency of the tax administration and the ability of manufacturers to translate these savings into lower market prices for consumers.
The Ministry of Health and Social Welfare is expected to monitor the impact of these waivers on the availability and pricing of essential drugs in the coming months to ensure the objectives of the executive order are met.
Explore more Business stories from Business Elites Africa.
